Cagrilintide

同義語： Cagrilintide, AM833, NNC 0172-2027, Long-acting amylin analog, CagriSema component

As the demand for more effective obesity treatments grows, the pharmaceutical industry is turning to multi-receptor agonists and combination therapies. Cagrilintide, a long-acting amylin analog, has emerged as a key building block in this new wave, particularly in combination with semaglutide (CagriSema). This peptide is drawing attention for its potential to enhance satiety and improve glycemic control, making it a focus for companies developing next-generation metabolic drugs.

Cagrilintide is a synthetic peptide engineered to mimic the action of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. By modifying the native amylin structure, researchers have achieved a longer half-life and improved solubility, allowing for once-weekly dosing. The peptide is typically produced via solid-phase peptide synthesis and purified to high homogeneity.

In the supply chain, Cagrilintide is available in research-grade and GMP-grade qualities. Standard specifications require ≥98% purity by HPLC, with strict control of counterions, residual solvents, and microbial limits. Our offering targets formulation scientists and API purchasers who need reliable material for preclinical and clinical development.

製品の概要と成分

Cagrilintide is a 37-amino acid peptide with a molecular weight of approximately 4387 Da. Its sequence incorporates non-natural amino acids and a fatty acid side chain that promotes albumin binding, extending its duration of action. The molecule is supplied as a lyophilized powder, often as the acetate salt to enhance stability and solubility.

Because it is manufactured by chemical synthesis, impurity profiles are carefully monitored. Typical impurities include deletion peptides, truncated sequences, and oxidation products. High-purity material is essential for reproducible biological assays and for meeting regulatory requirements in clinical trials.

主な用途

• Obesity and metabolic research: Used to study amylin receptor signaling and its effects on appetite suppression and energy balance.
• Combination therapy development: Evaluated alongside GLP-1 agonists like semaglutide to assess synergistic effects on weight loss and glucose control.
• Preclinical pharmacology: Employed in animal models to characterize pharmacokinetics and pharmacodynamics of long-acting amylin analogs.
• Formulation science: Investigated for stability, aggregation behavior, and delivery strategies for peptide therapeutics.
• Analytical method development: Serves as a reference standard for HPLC, LC-MS, and other analytical techniques.

品質と基準

包装・供給

• パッケージ: Supplied in amber glass vials with rubber stoppers and aluminum seals, each containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of peptide. Custom packaging available upon request.
• 最小注文数量（MOQ）: 10 mg for research-grade; 100 mg for GMP-grade.
• リードタイム: 3～5営業日（在庫品）
• ドキュメント: COA, MSDS, TDS, and additional analytical data (HPLC, MS) provided with each shipment. For GMP-grade, a full regulatory package is available.

見積依頼

• リブバイオ株式会社. — メールアドレス： info@lyvbio.com